Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement Jan 13, 2025 08:00AM
Salarius Pharmaceuticals (SLRX) Issues Update on Strategic Review Process, Will Support Ongoing Seclidemstat Clinical Trials by Further Cost Cuts Feb 22, 2024 08:00AM
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses Feb 22, 2024 08:00AM
Salarius Pharmaceuticals, Inc. (SLRX) Issued U.S. Patent for Next-Generation Targeted Protein Degraders Jan 16, 2024 08:17AM
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders Jan 16, 2024 08:00AM


Jan 3, 2024 08:54AM Salarius Pharmaceuticals (SLRX) Announces FDA Removal of Clinical Hold on Seclidemstat Trial
Jan 3, 2024 08:30AM Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Nov 7, 2023 08:31AM Salarius Pharmaceuticals, Inc. (SLRX) Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Nov 7, 2023 08:30AM Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Aug 8, 2023 04:10PM Salarius Pharmaceuticals (SLRX) Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
Aug 8, 2023 04:05PM Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources